Brainstorm Cell Therapeutics, Inc. (BCLI)
0.8645
+0.01
(+1.71%)
USD |
OTCM |
Jun 18, 16:00
Brainstorm Cell Therapeutics SG&A Expense (Quarterly) : 1.284M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 1.284M |
| December 31, 2025 | 1.392M |
| September 30, 2025 | 1.148M |
| June 30, 2025 | 1.453M |
| March 31, 2025 | 1.785M |
| December 31, 2024 | 1.466M |
| September 30, 2024 | 2.003M |
| June 30, 2024 | 2.06M |
| March 31, 2024 | 1.513M |
| December 31, 2023 | 3.106M |
| September 30, 2023 | 2.705M |
| June 30, 2023 | 2.655M |
| March 31, 2023 | 2.227M |
| December 31, 2022 | 2.464M |
| September 30, 2022 | 3.065M |
| June 30, 2022 | 2.478M |
| March 31, 2022 | 2.859M |
| December 31, 2021 | 2.535M |
| September 30, 2021 | 1.659M |
| June 30, 2021 | 2.522M |
| March 31, 2021 | 2.588M |
| December 31, 2020 | 2.671M |
| September 30, 2020 | 2.618M |
| June 30, 2020 | 1.706M |
| March 31, 2020 | 2.36M |
| Date | Value |
|---|---|
| December 31, 2019 | 1.479M |
| September 30, 2019 | 1.543M |
| June 30, 2019 | 1.303M |
| March 31, 2019 | 1.472M |
| December 31, 2018 | 1.577M |
| September 30, 2018 | 1.257M |
| June 30, 2018 | 1.606M |
| March 31, 2018 | 1.33M |
| December 31, 2017 | 1.329M |
| September 30, 2017 | 1.224M |
| June 30, 2017 | 0.64M |
| March 31, 2017 | 0.829M |
| December 31, 2016 | 0.327M |
| September 30, 2016 | 0.848M |
| June 30, 2016 | 0.832M |
| March 31, 2016 | 0.826M |
| December 31, 2015 | 0.571M |
| September 30, 2015 | 1.068M |
| June 30, 2015 | 0.988M |
| March 31, 2015 | 0.96M |
| December 31, 2014 | 1.023M |
| September 30, 2014 | 0.856M |
| June 30, 2014 | 0.417M |
| March 31, 2014 | 0.351M |
| December 31, 2013 | 0.527M |
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| NovelStem International Corp. | 0.005M |
| Summit Therapeutics, Inc. | 62.59M |
| Kezar Life Sciences, Inc. | 5.208M |
| Protara Therapeutics, Inc. | 6.067M |
| Clene, Inc. | 1.747M |